- Home
- ONCO vs EVAX Comparison
ONCO vs EVAX Comparison
Compare ONCO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- EVAX
- Stock Information
- Founded
- ONCO 2018
- EVAX 2008
- Country
- ONCO United States
- EVAX Denmark
- Employees
- ONCO N/A
- EVAX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONCO Health Care
- EVAX Health Care
- Exchange
- ONCO Nasdaq
- EVAX Nasdaq
- Market Cap
- ONCO 1.8M
- EVAX 17.8M
- IPO Year
- ONCO 2022
- EVAX 2021
- Fundamental
- Price
- ONCO $3.10
- EVAX $2.90
- Analyst Decision
- ONCO
- EVAX Strong Buy
- Analyst Count
- ONCO 0
- EVAX 2
- Target Price
- ONCO N/A
- EVAX $10.00
- AVG Volume (30 Days)
- ONCO 46.2K
- EVAX 89.0K
- Earning Date
- ONCO 08-14-2025
- EVAX 10-30-2025
- Dividend Yield
- ONCO N/A
- EVAX N/A
- EPS Growth
- ONCO N/A
- EVAX N/A
- EPS
- ONCO N/A
- EVAX N/A
- Revenue
- ONCO $1,326,959.00
- EVAX $3,176,000.00
- Revenue This Year
- ONCO N/A
- EVAX N/A
- Revenue Next Year
- ONCO N/A
- EVAX N/A
- P/E Ratio
- ONCO N/A
- EVAX N/A
- Revenue Growth
- ONCO N/A
- EVAX 1042.45
- 52 Week Low
- ONCO $2.61
- EVAX $1.20
- 52 Week High
- ONCO $552.50
- EVAX $17.20
- Technical
- Relative Strength Index (RSI)
- ONCO 51.38
- EVAX 50.88
- Support Level
- ONCO $2.64
- EVAX $2.71
- Resistance Level
- ONCO $3.17
- EVAX $3.04
- Average True Range (ATR)
- ONCO 0.16
- EVAX 0.20
- MACD
- ONCO 0.07
- EVAX -0.01
- Stochastic Oscillator
- ONCO 82.14
- EVAX 55.97
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.